Effects of luseogliflozin and voglibose on high-risk lipid profiles and inflammatory markers in diabetes patients with heart failure

Sodium-glucose cotransporter 2 inhibitors could reduce cardiovascular events in patients with heart failure irrespective of diabetes status. In this prespecified sub-analysis of randomised-controlled trial, we investigated the efficacy of luseogliflozin (2.5 mg daily), a sodium–glucose cotransporter...

Descripción completa

Detalles Bibliográficos
Autores principales: Ejiri, Kentaro, Miyoshi, Toru, Kihara, Hajime, Hata, Yoshiki, Nagano, Toshihiko, Takaishi, Atsushi, Toda, Hironobu, Namba, Seiji, Nakamura, Yoichi, Akagi, Satoshi, Sakuragi, Satoru, Minagawa, Taro, Kawai, Yusuke, Nishii, Nobuhiro, Fuke, Soichiro, Yoshikawa, Masaki, Nakamura, Kazufumi, Ito, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9474821/
https://www.ncbi.nlm.nih.gov/pubmed/36104378
http://dx.doi.org/10.1038/s41598-022-19371-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9474821/
https://www.ncbi.nlm.nih.gov/pubmed/36104378
http://dx.doi.org/10.1038/s41598-022-19371-6

Ejemplares similares